★ Analysts see FY2028 revenue reaching $4.0B — +5.0% growth in a single year.
What Moves the Stock
01M&A announcements and integration execution - company has pursued aggressive roll-up strategy, with market reacting to acquisition multiples and synergy realization
02Australian healthcare capital expenditure trends - hospital equipment replacement cycles and government healthcare infrastructure spending directly impact capital equipment sales
03Operating cash flow conversion - negative FCF despite positive earnings raises concerns about working capital management and acquisition integration costs
04Margin trajectory - ability to expand 2.5% operating margin through procurement synergies and overhead rationalization critical to equity story
05Medical device and equipment distribution (estimated 45-50% of revenue) - capital equipment sales to hospitals and healthcare facilities
06Healthcare consumables and supplies (estimated 35-40%) - recurring revenue from disposable medical products, surgical supplies, and infection control products
07Service and maintenance contracts (estimated 10-15%) - ongoing equipment servicing, calibration, and technical support
value - The 0.1x P/S, 1.1x P/B, and 6.9x EV/EBITDA multiples indicate deep value territory…
Rising rates negatively impact Paragon through multiple channels: (1) Higher financing costs on 0.93x debt/equity leverage used to fund…
Watch on earnings: Australian healthcare capital expenditure (public hospital infrastructure spending) - leading indicator for equipment sales demand, Elective surgery volumes in Australia/NZ - drives consumables utilization rates, Working capital as percentage of revenue - critical for cash flow normalization.
One Sentence Summary:
Paragon Care: the story is balanced — m&a announcements and integration execution - company has pursued aggressive roll-up strategy.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
